TickerFacts.

Impact Biomedical Inc. (IBO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$3.14M
Year ended 2025-12-31
-$3.96M
Trailing 12 months to 2026-06-30
2022-12-31: -$2.29M2023-12-31: -$2.91M2024-12-31: -$27.63M2025-12-31: -$3.14M-$3.14M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$3.14Mn/m2026-03-11, From 2025-01-01
2024-12-31-$27.63Mn/m2026-03-11, From 2024-01-01
2023-12-31-$2.91Mn/m2025-03-28, From 2023-01-01
2022-12-31-$2.29Mn/a2024-02-20, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Impact Biomedical Inc. (IBO)2025-12-31-$3.14Mn/m
Lyell Immunopharma, Inc. (LYEL)2025-12-31-$257.87Mn/m
Talphera, Inc. (TLPH)2024-12-31-$15.25Mn/m
Skinvisible, Inc. (SKVI)2025-12-31-$476.1Kn/m
HCW Biologics Inc. (HCWB)2025-12-31-$12.12Mn/m
Avalo Therapeutics, Inc. (AVTX)2025-12-31-$72.58Mn/m
Connect Biopharma Holdings Ltd (CNTB)2025-12-31-$57.37Mn/m
Incannex Healthcare Inc. (IXHL)2025-06-30-$23.54Mn/m
Actinium Pharmaceuticals, Inc. (ATNM)2025-12-31-$36.07Mn/m

Compare IBO, LYEL, TLPH, SKVI side by side · Screen every company in Pharmaceutical Preparations ↗